Azathioprine

證據等級: L5

預測適應症: 10 個

Azathioprine: Evaluation Report — Insufficient Data for Repurposing Assessment

One-Sentence Summary

Azathioprine (DB00993) is a candidate submitted for TxGNN drug repurposing evaluation. However, this Evidence Pack contains no predicted new indications, no mechanism of action data, and no safety information, making a complete repurposing assessment impossible at this stage. A data remediation effort is required before evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	No TxGNN predictions generated
TxGNN Prediction Score	N/A
Evidence Level	N/A — No predictions available
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Finland Market Information

Azathioprine currently holds no marketing authorizations in Finland according to the data queried on 2026-03-29. No product listings, dosage forms, or approved indications are on record.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Azathioprine is missing all three elements required for a repurposing evaluation: TxGNN predictions, mechanism of action data, and safety/contraindication information. No recommendation for or against repurposing can be issued until these gaps are resolved.

To proceed, the following is needed:

[Blocking] Predicted Indications: The predicted_indications array is empty. Re-run the TxGNN pipeline for DB00993 to generate candidate indications with scores, supporting clinical trials, and literature.
[Blocking] Safety Data (DG001): Key warnings and contraindications were not retrieved. Download and parse the package insert PDF from the relevant regulatory authority to enable the S1 safety pre-screening step.
[High] Mechanism of Action (DG002): MOA data is absent. Query the DrugBank API for DB00993 to populate original_moa, which is required for the mechanistic rationale section of the evaluation.
[Recommended] Original Indications: The original_indications field is empty. Populate this from DrugBank or the package insert to enable the "From X to Y" repurposing narrative.

Once the above data gaps are resolved and the Evidence Pack is regenerated at v5 or later, a full evaluation report can be produced.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.